Table 3.

Late IL-4 Administration Restores Resistance and CD4⁺ Th1 Cytokine Production in C. albicans–infected IL-4^−/− Mice

Mice*		Treatment†						MST		CFU × 103§		Cytokine production‖
		rIL-4		mAb Anti-Ly6G		mAb Anti–IL-4						IFN-γ (ng/ml)		IL-2 (U/ml)
IL-4−/−		−		−		−		7		1,220 ± 89		<0.1		64 ± 5
IL-4−/−		+		−		−		27¶		360 ± 65¶		78 ± 10		156 ± 14
IL-4−/−		−		+		−		4		3,530 ± 148		19 ± 3		50 ± 8
IL-4−/−		+		+		−		11¶		1,047 ± 111¶		48 ± 8		144 ± 28
IL-4+/+		−		−		−		>60		225 ± 81		81 ± 13		187 ± 17
IL-4+/+		+		−		−		>60		304 ± 102		119 ± 12		148 ± 24
IL-4+/+		−		−		+		21**		581 ± 94		24 ± 3		89 ± 9
IL-4+/+		−		+		−		5		2,824 ± 177		29 ± 4		66 ± 10
IL-4+/+		+		+		−		14¶		811 ± 79¶		54 ± 2		104 ± 15

^* Mice were infected intravenously with 10⁶ PCA-2 and reinfected 14 d later with 10⁶ CA-6.  

^† Treatment with rIL-4 (12 μg total dose, given together with the 11B11 anti–IL-4 mAb) or with the 11B11 mAb (2 mg, total dose) was done every other day from 6 to 12 d after primary PCA-2 infection. The neutrophil-depleting mAb (anti-Ly6G) was given intraperitoneally (100 μg/mouse) 2 d before reinfection. Neutrophil-depleted mice were treated twice with rIL-4 (as above) 2 and 1 d before reinfection.  

^§ Colony forming units in the kidneys at 3 d after reinfection.  

^‖ Cytokine contents of supernatants of CD4⁺ T cells from spleens of 3-d reinfected mice cultured in vitro with C. albicans antigen and accessory macrophages.  

^¶ P <0.05 Student's t test (rIL-4–treated versus untreated mice).  

^** P <0.05 Student's t test (anti–IL-4 mAb-treated versus untreated IL-4^+/+ mice).